ArticleNew microbes and new infections2022
Carbapenem resistance associated with coliuria among outpatient and hospitalised urology patients.
Article in New microbes and new infections, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Prevalence of carbapenem-resistantPathogens and global healthPooled it
- Diagnostic performance of rapid screening tests for asymptomatic bacteriuria among pregnant women in a tertiary care hospital in India.Scientific reports · 2026Article
- High prevalence of co-trimoxazole and carbapenem resistance among uropathogenic bacteria from a community hospital in New Delhi, India.Molecular biology reports · 2025Article
- Challenges in the Treatment of Urinary Tract Infections: Antibiotic Resistance Profiles ofBiomedicines · 2025Article
- Environmental Risk Factors Contributing to the Spread of Antibiotic Resistance in West Africa.Microorganisms · 2025Review
- High prevalence of carbapenem-resistantHeliyon · 2024Article
- Decline in ESBL Production and Carbapenem Resistance in Urinary Tract Infections among Key Bacterial Species during the COVID-19 Pandemic.Antibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization in 2017 listed carbapenem resistant Enterobacteriaceae (CRE) with critical priority for research. A research to assess carbapenem resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.